Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Bortezomib market france?Sun pharma bortezomib?Defense strategy against generic in niche market?What are the most memorable drug brands in oral factor b inhibitors? in united statesProlia and osteonecrosis?
See the DrugPatentWatch profile for Saphnelo
Saphnelo (anifrolumab-fnia) is given as an intravenous (IV) infusion. The standard dosing is 300 mg once every 4 weeks. [1]
For Saphnelo, the labeled regimen is fixed at 300 mg every 4 weeks and is not adjusted by body weight. The provided dosing information also does not describe dose changes based on age or specific comorbidities. [1]
Because the regimen is once every 4 weeks, patients typically plan clinic visits at a monthly interval. Each visit involves an IV infusion of the 300 mg dose. [1]
The dosing guidance for missed doses is not included in the provided information. If you tell me what date your last infusion was and when the missed dose would be due, I can help you phrase the question for your prescriber/pharmacy, but I can’t calculate a specific make-up schedule from the available data. [1]
The provided information does not include dosing-specific monitoring instructions or safety adjustments. Standard practice is to follow the prescribing information and the infusion-center protocol for infusion reactions and related safety monitoring. [1] --- Sources: 1. https://www.ema.europa.eu/en/medicines/human/EPAR/saphnelo
Other Questions About Saphnelo :